Getinge’s Q2 “broadly in line”
This article was originally published in Clinica
Swedish medtech firm Getinge may have problems reaching its full-year targets after a weak first half of 2012, according to Jefferies analyst Ingeborg Øie. She described the firm’s second fiscal quarter performance as “mixed”, but “broadly in-line”. The firm reported Q2 group sales of SEK5.61bn ($805.9m), up 13% (+0.4% on constant currency basis) and close to Jefferies estimate of SEK5.598bn, but 1% below consensus analyst expectations. Getinge has reiterated its outlook for full-year 2012, saying it expects to see organic sales growth higher than the 4.2% posted in 2011, as well as profit growth. But Ms Øie cautioned: “Our and consensus organic growth estimates of 4.1% and 4.2%, respectively, would put in question whether the full-year growth target can be reached after these weak results.”
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.